相关实验视频

Updated: May 17, 2025

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

由trastuzumab引起的不可逆转心脏毒性:基于药监病例报告的系统审查

Víctor E Lechuga-Noa^1,2, L Yesenia Rodríguez-Tanta², Tania Del Pilar Solis-Yucra²

¹Instituto Nacional Cardiovascular - INCOR- EsSalud, Lima, Perú. Instituto Nacional Cardiovascular - INCOR- EsSalud Lima Perú.

Archivos peruanos de cardiologia y cirugia cardiovascular

|May 16, 2025

概括

特拉斯图祖马布 (TZB) 可以导致不可逆转的心脏毒性 (IC),这是一个严重的副作用. 这项研究突出了TZBB.

科学领域:

在瘤学瘤学.
心脏病学心脏病学
药物监督药物监督药物监督

背景情况:

特拉斯图祖马布 (TZB) 是一种有效的抗瘤药物.
不可逆转的心脏毒性 (IC) 是一种与TZB相关的罕见但严重的不良事件.
由于TZB诱导的IC的特征和暴露因子尚不清楚.

研究的目的:

综合和评价现有证据,以分析特斯图祖马布 (TZB) 诱导的不可逆转心脏毒性 (IC).
报告一个长期IC病例,并对全球病例进行系统审查.

主要方法:

根据CARE的指导方针,报告了一起药监情况.
使用PRISMA指南对五个案例报告进行了系统审查.
搜索的数据库包括PubMed,Embase,Scopus和Web of Science从创立到2023年6月.
使用修改的卡尔赫和拉萨尼亚算法评估了因果关系.

主要成果:

在所有病例中观察到一致的TZB剂量为6mg/kg.
诊断IC的中位时间为10个月.
发现左心室喷射小部分的平均显著减少约为30%.
所有审查的病例都被归类为可能的或可能的TZB诱导的IC.

结论:

临床医生和监管机构必须认识到特拉斯图祖马布 (TZB) 的长期不可逆转心脏毒性 (IC) 的潜力.
对于接受TZB的患者来说,警的心脏监测是必不可少的.
需要进一步的研究,以充分理解和管理TZB诱导的IC.

关键词:

乳腺新生体乳腺新生体心脏有毒性 - 心脏有毒性药物监督药物监督药物监督这就是Trastuzumab.

更多相关视频

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

相关概念视频

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Electron Transport Chain: Complex I and II

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...